Insights of Keloids Pipeline Review H2 2016 and Therapeutic Development
Keloids Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Keloids therapeutics industry report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news...
View full press release